Meeting
2018 Gastrointestinal Cancers Symposium
Is there any survival benefit of additional chemotherapy (C) following adjuvant C in pancreatic cancer (PC) patients (pts) with postsurgery elevated CA19-9?
Authors
Wasif M. Saif
Tufts University School of Medicine, Boston, MA
Wasif M. Saif , Melissa H Smith , Martin D. Goodman , Suzanne M. Russo , Kathryn Huber , Ronald R Salem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 491)
DOI
10.1200/JCO.2018.36.4_suppl.491
Abstract #
491
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Evaluation of the CpG island methylator phenotype as a predictive biomarker for adjuvant oxaliplatin-based chemotherapy in colorectal cancer.
First Author: Stacey Shiovitz
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2018 Gastrointestinal Cancers Symposium
Role of adjuvant therapy in resected gallbladder cancer.
First Author: Mohamed Abdelrahim Muddathir Hassan
Poster
2017 Gastrointestinal Cancers Symposium
Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A “REAL LIFE” study.
First Author: Guido Giordano